Compare Summit Therapeutics Inc (SMMT) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Toronto-Dominion Bank — how do they compare? Summit Therapeutics Inc trades at $17.58 (market cap $13.98B), while Toronto-Dominion Bank trades at $119.14 (market cap $195.86B). The key difference: Toronto-Dominion Bank is far larger — about 14× Summit Therapeutics Inc's market cap, and Toronto-Dominion Bank pays a 2.72% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | TD | |
|---|---|---|
Market Cap | $13.98B | $195.86B |
Sector | Health | Financials |
52-Week High | $26.38 | $124.80 |
52-Week Low | $12.43 | $75.86 |
Enterprise Value | $13.31B | — |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
TD stock trades at $120.52, down 0.91% today, with a neutral technical signal. The company reported strong Q3 2026 earnings, beating estimates with a profit of $4.62 billion, driven by capital markets and cost controls. Revenue growth is steady, with 2025 revenue at $61.28 billion and net income margin of 24.88%. Analyst consensus is bullish with 9 buy ratings and no sells. Recent news highlights AI value generation and participation in tokenized payments tests.
Outlook remains positive given earnings momentum and dividend stability, but risks include high debt levels and macroeconomic sensitivity. The stock offers value with a P/E of 17.85 and consistent dividend payments, though competition and interest rate fluctuations pose challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
